Overview

Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease

Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
To provide parenteral fat emulsion prepared from fish oil (omega-3 fatty acid emulsion, Omegaven®) to patients with liver disease (PNALD).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Children's Mercy Hospital Kansas City